Avacta Group Share News (AVCT)

Avacta Says Non-Executive Director Michael Albin To Stand Down Friday

LONDON (Alliance News) - Avacta Group PLC, a healthcare products company that specialises in Affimer products that bind molecules together, said Thursday that non-executive be

DIRECTOR DEALINGS: Avacta Chief Executive Officer Smith Buys Shares

LONDON (Alliance News) - Avacta Group PLC said its Chief Executive Officer Alastair Smith bought shares in the biotechnology company in transaction on Tuesday.Smith at

Avacta expects licensing deal for therapeutics product in 2017, order book swells

(ShareCast News) - Life science firm Avacta expects to have its first licensing deal for Affirmer, its biotherapeutics product, this year as its order book swelled. In an update for the six months ended 31 January, the the company said that its order book for Affimer grew 70% year-on-year, which alo

Avacta Adds Cancer Stem Cell Specialist Evan To Scientific Board

Avacta announces collaboration with Memorial Sloan Kettering Cancer Center

(ShareCast News) - Avacta Group announced a research collaboration with Memorial Sloan Kettering Cancer Center on Wednesday, to evaluate the use of the company's 'Affimer' technology in novel CAR-T cell-based immunotherapy. The AIM-traded firm said CAR-T immunotherapy is a form of cancer treatment i

Avacta Group narrows loss as revenues rise

(ShareCast News) - Biotherapeutic, research and diagnostic reagent developer Avacta Group announced its preliminary results for the year to 31 July on Monday, with revenues and losses in line with market expectations. The AIM-traded company said it was well funded at period end, with cash balances o

Avacta reveals positive results from Affirmer studies

(ShareCast News) - Affimer biotherapeutics and research reagents developer Avacta Group announced positive results from the first preclinical in-vivo studies of its therapeutic Affimer molecules on Thursday. The AIM-traded company said the results meaningfully de-risk the development of the technolo

Avacta Reports Good First Results From Affimer Pre-Clinical Trials

Avacta collaboration programme gets £3.8m grant

(ShareCast News) - A collaboration programme between AIM-listed Avacta and Leeds University has been awarded a £3.8m grant by the Medical Research Council. The biotherapeutics and research reagents developer said the grant was to develop novel, rapid diagnostic tools incorporating Affimer reagents,

Avacta-Leeds University Partnership Gets GBP3.8 Million Grant

Avacta granted European patent for Affimer technology

(ShareCast News) - European and US regulators handed down further patent decisions in favour of Avacta´s Affimer biotherapeutics and research reagents, helping the company to consolidate its intelectual property portfolio. In Europe, authorities granted the Life Sciences group the main patent for it

Avacta revenue in line with forecasts, but losses mount

(ShareCast News) - Life sciences company Avacta said on Monday that revenue for the year to the end of July grew by around 19% but losses nearly doubled due to a change in accounting policy. In a pre-close trading update ahead of its preliminary results for the year to the end of July, Avacta said r

Avacta Collaborating With Glythera To Develop Antibody Drugs

Avacta claims development could lead to early Zika diagnosis

(ShareCast News) - Avacta, biotherapeutics and research agent developer, reported on Wednesday it had identified three proteins which could be used to develop the first tests to diagnose early stages of the Zika virus. Avacta said it found three 'Affimer' proteins capable of binding to a form of sec

Avacta Identifies Affimer Proteins For Possible Zika Virus Tests